Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000410667 | SCV000486030 | likely pathogenic | Dihydropyrimidine dehydrogenase deficiency | 2016-04-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000410667 | SCV000894212 | pathogenic | Dihydropyrimidine dehydrogenase deficiency | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000410667 | SCV000917300 | likely pathogenic | Dihydropyrimidine dehydrogenase deficiency | 2023-03-06 | criteria provided, single submitter | clinical testing | Variant summary: DPYD c.661G>T (p.Glu221X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 3.2e-05 in 250946 control chromosomes (gnomAD). To our knowledge, c.661G>T has not been reported in the literature in individuals affected with Dihydropyrimidine Dehydrogenase Deficiency and no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Genome- |
RCV000410667 | SCV004049561 | likely pathogenic | Dihydropyrimidine dehydrogenase deficiency | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000410667 | SCV004194080 | pathogenic | Dihydropyrimidine dehydrogenase deficiency | 2024-02-07 | criteria provided, single submitter | clinical testing |